Nearly half of the 1,500 surveyed physicians said they had not prescribed Paxlovid to older people because the patient had another medication that could not be discontinued and the drug is contraindicated with Paxlovid. In the same vein, about 2 in 5 said the risk of discontinuing a patient’s medication was too high.
Concerns about the drug’s rebound risk accounted for 22 percent of hesitation to prescribe the antiviral.
The public’s use of Paxlovid has been declining, but this study offers a new potential explanation for its slow fall in popularity.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
